Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AL-38583 ophthalmic solution
AL-38583 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AL-38583 0.01% | EXPERIMENTAL | AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks |
| AL-38583 0.05% | EXPERIMENTAL | AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks |
| AL-38583 0.2% | EXPERIMENTAL | AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks |
| AL-38583 Vehicle | PLACEBO_COMPARATOR | AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks |
| MAXIDEX | ACTIVE_COMPARATOR | Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks |
| Name | Type | Description |
|---|---|---|
| AL-38583 ophthalmic solution | DRUG | - |
| AL-38583 ophthalmic solution vehicle | DRUG | Inactive ingredients used as a placebo comparator |
| Dexamethasone ophthalmic suspension, 0.1% | DRUG | - |
Inclusion Criteria: * Presence of signs and symptoms of ocular inflammation in both eyes. * Have a positive CAC response at Visit 1. * Able to avoid the use of disallowed medications as well as contact lens wear for the specified period prior to Visit 1, and for the duration of the study. * Other p...
AL-38583 is an investigational ophthalmic solution being developed for allergic conjunctivitis and the associated inflammation of the eye. It is a small molecule formulated for topical use in the eye. Alcon Inc. has studied it in a Phase 2 clinical trial in adults with allergic conjunctivitis.
AL-38583 is developed by Alcon Inc., which trades under the ticker ALC. Alcon is an eye care company, and AL-38583 is part of its ophthalmology pipeline. The drug is an ophthalmic solution small molecule being studied for allergic conjunctivitis.
AL-38583 is in Phase 2 development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial of AL-38583 has been completed, and no trials of the drug are currently listed as active.
AL-38583 has been studied in the Phase 2 trial NCT01001091, titled AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation. That trial enrolled 312 participants, was randomized, double blind, and placebo controlled, and it is now completed. Participants were adults 18 years and older.
Yes. AL-38583 ophthalmic solution is the same asset as AL-38583, referring to the topical eye drop formulation studied in clinical trials. Searches for either name point to the same Alcon Inc. development program for allergic conjunctivitis.